News + Filings Transactions
|
Agarwal Shefali
Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
06/06/2023 | FATE THERAPEUTICS INC | FATE | Grant | Stock Option (Right to Buy) | 40k | $5.52 | $220.8k | | 06/06/2023 |
08/12/2022 | Epizyme, Inc. | EPZM | Disposition | Common Stock, par value $0.0001 | 107.3k | $0.00 | $0 | | 08/12/2022 |
08/12/2022 | Epizyme, Inc. | EPZM | Disposition | Common Stock, par value $0.0001 | 179.2k | $0.00 | $0 | | 08/12/2022 |
08/09/2022 | Epizyme, Inc. | EPZM | Exercise | Stock Option (Right to Buy) | 400k | $1.39 | $556k | | 08/09/2022 |
08/09/2022 | Epizyme, Inc. | EPZM | Payment of Exercise | Common Stock, par value $0.0001 | 373.2k | $1.39 | $518.7k | | 08/09/2022 |
08/09/2022 | Epizyme, Inc. | EPZM | Exercise | Stock Option (Right to Buy) | 56.5k | $1.39 | $78.6k | | 08/09/2022 |
08/09/2022 | Epizyme, Inc. | EPZM | Exercise | Stock Option (Right to Buy) | 43.5k | $1.39 | $60.4k | | 08/09/2022 |
06/17/2022 | Gritstone bio, Inc. | GRTS | Grant | Stock Option (Right to Buy) | 19k | $2.22 | $42.2k | | 06/17/2022 |
06/09/2022 | FATE THERAPEUTICS INC | FATE | Grant | | 8.6k | $0.00 | $0 | | 06/09/2022 |
06/09/2022 | FATE THERAPEUTICS INC | FATE | Grant | Stock Option (Right to Buy) | 11.9k | $23.48 | $279.2k | | 06/09/2022 |
06/07/2022 | FATE THERAPEUTICS INC | FATE | Sale | Common Stock | 841 | $21.89 | $18.4k | | 06/07/2022 |
06/03/2022 | FATE THERAPEUTICS INC | FATE | Sale | Common Stock | 807 | $22.80 | $18.4k | | 06/03/2022 |
03/17/2022 | Epizyme, Inc. | EPZM | Grant | Stock Option (Right to Buy) | 500k | $1.39 | $695k | | 03/17/2022 |
02/28/2022 | Epizyme, Inc. | EPZM | Grant | Common Stock | 2.3k | $1.27 | $3k | | 03/17/2022 |
02/07/2022 | Epizyme, Inc. | EPZM | Sale | Common Stock, par value $0.0001 | 1.1k | $1.50 | $1.6k | | 02/07/2022 |
02/02/2022 | Epizyme, Inc. | EPZM | Sale | Common Stock, par value $0.0001 | 2.6k | $1.37 | $3.6k | | 02/02/2022 |
01/26/2022 | Epizyme, Inc. | EPZM | Sale | Common Stock, par value $0.0001 | 2.9k | $2.02 | $5.9k | | 01/26/2022 |
12/06/2021 | Epizyme, Inc. | EPZM | Sale | Common Stock, par value $0.0001 | 1.8k | $2.93 | $5.2k | | 12/06/2021 |
06/18/2021 | Gritstone bio, Inc. | GRTS | Grant | Stock Option (Right to Buy) | 937 | $9.86 | $9.2k | | 06/18/2021 |
06/02/2021 | FATE THERAPEUTICS INC | FATE | Grant | | 2.7k | $0.00 | $0 | | 06/02/2021 |
06/02/2021 | FATE THERAPEUTICS INC | FATE | Grant | Stock Option (Right to Buy) | 4.3k | $68.94 | $298.8k | | 06/02/2021 |
06/01/2021 | Gritstone bio, Inc. | GRTS | Grant | Stock Option (Right to Buy) | 38k | $9.48 | $360.2k | | 06/01/2021 |
02/04/2021 | Epizyme, Inc. | EPZM | Sale | Common Stock, par value $0.0001 | 969 | $11.21 | $10.9k | | 02/04/2021 |
02/01/2021 | Epizyme, Inc. | EPZM | Grant | Common Stock | 29.6k | $0.00 | $0 | | 02/01/2021 |
02/01/2021 | Epizyme, Inc. | EPZM | Grant | Stock Option (Right to Buy) | 141.1k | $11.02 | $1.6M | | 02/01/2021 |
01/25/2021 | Epizyme, Inc. | EPZM | Sale | Common Stock, par value $0.0001 | 2.9k | $11.41 | $32.8k | | 01/25/2021 |
12/03/2020 | Epizyme, Inc. | EPZM | Sale | Common Stock, par value $0.0001 | 2.5k | $13.54 | $34.1k | | 12/03/2020 |
06/26/2020 | Epizyme, Inc. | EPZM | Sale | Common Stock, par value $0.0001 | 1.8k | $16.15 | $29.2k | | 06/25/2020 |
06/25/2020 | Epizyme, Inc. | EPZM | Grant | Common Stock, par value $0.0001 | 6k | $0.00 | $0 | | 06/25/2020 |
05/01/2020 | FATE THERAPEUTICS INC | FATE | Grant | Stock Option (right to buy) | 16k | $26.59 | $425.4k | | 05/01/2020 |
03/25/2020 | Epizyme, Inc. | EPZM | Sale | Common Stock, par value $0.0001 | 1.2k | $15.28 | $19k | | 03/24/2020 |
03/24/2020 | Epizyme, Inc. | EPZM | Grant | Common Stock, par value $0.0001 | 1.6k | $0.00 | $0 | | 03/24/2020 |
02/03/2020 | Epizyme, Inc. | EPZM | Grant | Common Stock | 12.9k | $0.00 | $0 | | 02/03/2020 |
02/03/2020 | Epizyme, Inc. | EPZM | Grant | Stock Option (Right to Buy) | 61.8k | $21.39 | $1.3M | | 02/03/2020 |
01/27/2020 | Epizyme, Inc. | EPZM | Sale | Common Stock, par value $0.0001 | 2.6k | $20.44 | $53.8k | | 01/23/2020 |
|
|